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SUMMARY
We investigated the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR)
Damage Index as a predictor of severe outcome and an indicator of morbidity in different ethnic groups, and in regard to its
validity. We retrospectively studied disease course within 10 yr of diagnosis in an inception cohort of 80 patients with systemic
lupus erythematosus (SLE). The mean renal damage score (DS) at 1 yr after diagnosis was a significant predictor of endstage
renal failure and the mean pulmonary DS at 1 yr significantly predicted death within 10 yT of diagnosis. Compared to Caucasians,
Afro-Caribbeans and Asians had significantly higher mean total DS at 5 and 10 yr, and higher mean renal DS at 10 yr. At 5 yr,
the mean renal DS in Afro-Caribbeans and the mean neuropsychiatric DS in Asians were significantly higher than in Caucasians.
The rate of endstage renal failure in Caucasians was significantly lower than in the other ethnic groups. Our results confirm
the validity of the SLICC/ACR Damage Index.
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THE Systemic Lupus International Collaborative
Clinics/American College of Rheumatology (SLICC/
ACR) Damage Index, developed in 1992, was created
to assess persistent reflection of disease activity in SLE
patients and has been used in various 'paper' and real
patient studies [1]. Damage, that means irreversible
impairment, was defined as being continuously
persistent for at least 6 months. The index is shown in
Table la and b. In 1994, a weighted scoring system for
SLICC/ACR Damage Index was presented [2], based
upon the opinion of lupus experts. Our retrospective
study, based on the SLICC/ACR Damage Index, was
undertaken to investigate the following four questions.
Firstly can minor damage predict progression to major
damage? For example, parts of the renal damage score
(DS), such as a reduced glomerular filtration rate and
proteinuria, have been shown to be associated with the
subsequent development of renal insufficiency [3,4].
Similarly, prediction of death by the SLICC/ACR
Damage Index is also of interest. Secondly, can mor-
bidity becompared between different ethnic groups? As
survival in SLE patients has improved, comparison
of mortality between ethnic groups has become less
sensitive, but an analysis of morbidity may reveal other
differences. Thus, the SLICC/ACR Damage Index, as
an instrument of outcome assessment during lifetime,
seems likely to satisfy this purpose. Higher mortality
rates in Afro-Caribbeans [5,6] and Asians [7]
compared to Caucasians could reflect either more
severe disease, higher disease prevalence [8,9] or both
and could be paralleled by higher DS. Thirdly, would
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the answers to the first two questions be in accordance
with the literature and therefore demonstrate the
validity of the SLICC/ACR Damage Index? Fourthly,
would the weighted total DS [2] provide more insights
into systemic lupus erythematosus (SLE) than the
unweighted total DS?
PATIENTS AND METHODS
An inception cohort of all of our SLE patients in
whom the diagnosis was established at least 10 yr
prior to November 1994, and who had subsequently
attended a specialist lupus clinic, was studied. At
each out-patient consultation, detailed clinical and
serological information was recorded (and kept
separate from the hospital notes, although these were
also available for perusal). The SLICC/ACR Damage
Index was assessed retrospectively from the notes 1, 5
and 10 yr after diagnosis by the same rheumatologist
(TS). In the case of a lethal outcome, the last DS was
determined 6 months before death. The weighted total
DS was calculated by multiplying the neuropsychiatric,
renal and cardiovascular DS by four, the ocular,
pulmonary, peripheral vascular and malignancy DS by
three, and the gastrointestinal and musculoskeletal DS
by two, resulting in a potential maximum of 133 points
[2]. The date at which a patient fulfilled the fourth SLE
classification criterion [10] was recorded as the date of
diagnosis. Every patient was carefully reviewed for
evidence of having had a severe outcome within 10 yr
after diagnosis, defined as either death or endstage
renal failure (ESRF) necessitating dialysis. If a patient
had moved and had not been attending our out-patient
clinic, attempts were made to contact her/him and their
physicians to obtain the necessary data.
© 1996 British Society for Rheumatology
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TABLE la
SLICC/ACR Damage Index. Definition of damage: occurring since
onset of lupui, ascertained by clinical assessment and present Tor at
least 6 months unless otherwise stated. Repeat episodes mean at least
6 months apart to score 2. The same lesion cannot be scored twice.
A precise definition of items is contained in a glossary
Score
[maximal]Organ (system) Item
Ocular Any cataract ever I
Retinal change OR optic atrophy I [2]
Neuropsychiatric Cognitive impairment OR Major
psychosis 1
Seizures requiring therapy for
> 6 months 1
Cerebral vascular accident ever
(Score 2 if > l x ) O R
resection not for malignancy 1 (2)
Cranial or peripheral neuropathy
(excluding optic) 1
Transverse myelitis 1 [6]
Renal Estimated or measured GFR
< 50% 1
Proteinuria >3.5g/24h 1
ESRF (regardless of dialysis or
transplantation)* 1-3* [3]
Pulmonary Pulmonary hypertension (right
ventricular prominence
or loud P2) 1
Pulmonary fibrosis (clinically
and/or by X-ray) 1
Shrinking lung (by X-ray) 1
Pleura! fibrotis (by X-ray) 1
Pulmonary infarction (by X-ray)
OR resection not for malignancy 1 [5]
Cardiovascular Angina OR Coronary artery bypass I
Myocardial infarction ever
(Score 2 if > l x ) 1 (2)
Cardiomyopathy (ventricular
dysfunction) 1
Valvular disease (diastolk murmur,
or systolic murmur > 3/6) 1
Pericarditis OR Pericardiectomy 1 [6]
Peripheral vascular Claudication 1
Minor tissue loss (pulp space) 1
Significant tissue loss ever
(at least loss or resection of a
digit)
( S c o r e 2 i f > l x ) 1 (2)
Venous thrombosis with swelling,
ulceration OR venous stasis 1 [5]
Gastrointestinal Infarction or resection of bowel
below duodenum, spleen, liver or
gall bladder ever
(Score 2 if > 1 site) 1 (2)
Mesenteric insufficiency 1
Chronic peritonitis 1
Stricture OR Upper gastrointestinal
tract surgery ever 1
Pancreatic insufficiency requiring
enzyme replacement OR
with pseudocyst 1 [6]
Musculoskeletal Muscle atrophy OR weakness 1
Deforming or erosive arthritis
(including reducible deformities,
excluding AVN) 1
Osteoporosis with fracture or
vertebral collapse
(excluding AVN) 1
A vascular necrosis •= AVN
(Score 2 if > 1 x ) 1 (2)
Osteomyelitis 1 [6]
Skin
Gonadal
Endocrine
Malignancy
Scarring chronic alopecia
Extensive scarring of panniculum
other than scalp and pulp space
Skin ulceration (excluding
thrombosis) of more than
6 months
Premature gonadal failure
Diabetes requiring therapy.
regardless of treatment
Malignancy (exclude dysplasia)
(Score 2 i f> 1 site)
1
1
I
I
1
1 (2)
[2]
[1]
[1]
[2]
Potential maximum of the total ADI: 46 points.
•Adding up to a total renal DS of 3 points.
TABLE Ib
SLICC/ACR Damage Index: Glossary of terms
Damage:
Non-reversible change, not related to active inflammation,
occurring since onset of lupus, ascertained by clinical assessment
and present for at least 6 months unless otherwise stated. Repeat
episodes mean at least 6 months apart to score 2. The same
lesion cannot be scored twice.
Cataract:
A lens opacity in either eye, ever, whether primary or secondary
to steroid therapy, documented by ophthahnoscopy.
Retinal change:
Documented by ophthahnoscopic examination, may result in
field defect, legal blindness.
Optic atrophy:
Documented by ophthahnoscopic examination.
Cognitive impairment:
Memory deficit, difficulty with calculation, poor concentration,
difficulty in spoken or written language, impaired performance
level, documented on clinical examination or by formal
neurocognitive testing.
Major psychosis:
Altered ability to function in normal activity due to psychiatric
reasons. Severe disturbance in the perception of reality
characterized by the following features: delusions, hallucina-
tions, incoherence, marked loose associations, impoverished
thought content, marked illogical thinking, bizarre, disorganized
or catatonic behaviour.
Seizures:
Paroxysmal electrical discharge occurring in the brain and
producing characteristic physical changes including tonic and
clonk movements and certain behavioural disorders. Only
seizures requiring therapy for 6 months are counted as damage.
CVA:
Cerebral vascular accident resulting in focal findings such as
paresis, weakness etc., OR surgical resection for causes other
than malignancy.
Neuropathy:
Damage to either a cranial or a peripheral nerve (excluding
optic), resulting in eitheT motoric or sensory dysfunction.
Transverse myelitis:
Lower extremity weakness or sensory loss with loss of rectil and
urinary bladder sphincteT control.
Glomerular filtration rate (GFR):
Estimated or measured GFR <50%.
Cardiovascular
Myocardial infarction (documented by EKG and enzymes),
ever. Cardiomyopathy (ventricular dysfunction documented
clinically).
Peripheral vascular
Claudication persistent for 6 months, by history. Minor tissue
loss, such as pulp space, ever. Significant tissue loss, such as loss
of digit or limb, or resection, ever. Venous thrombosis with
swelling, ulceration, or clinical evidence of venous stasis.
continued continued overleaf
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TABLE Ib—continued
SLICC/ACR Damage Index: Glossary of terms
Gastrointestinal:
Infarction or resection of bowel below duodenum, by history.
Resection of spleen, liver or gall bladder ever, for whatever
cause. Mesenteric insufficiency, with diffuse abdominal pain, on
clinical examination. Chronic peritonitis, with persistent
abdominal pain and peritoneal irritations, on clinical
examination. Oesophageal stricture, shown on endoscopy.
Upper gastrointestinal tract surgery, such as correction of
stricture, ulcer surgery etc., ever, by history.
Musculoskeletal:
Muscle atrophy or weakness, demonstrated on clinical
examination. Deforming or erosive arthritis, including reducible
deformities, excluding a vascular necrosis, on clinical
examination. Osteoporosis with fracture or vertebral collapse
(excluding avascular necrosis), demonstrated on X-ray.
Avascular necrosis, demonstrated on any image technique.
Osteomyelitis, documented clinically, and supported by culture
evidence.
Skin:
Scarring chronic alopecia, documented clinically. Extensive
scarring or panniculum other than scalp and pulp space,
documented clinically. Skin ukeration (excluding thrombosis).
Premature gonadal failure:
Secondary amenorrhoea.
Malignancy:
Documented by pathology, excluding dysplasias.
Statistical analysis
The survival times to severe outcome were analysed
using Cox regression. Damage scores and severe
outcomes, respectively, were compared beween differ-
ent ethnic groups by the Kruskal-Wallis rank test and
Fisher's exact test for contingency tables. In case of an
overall difference at P < 0.1, pairwise differences were
tested using the Mann-Whitney rank and Fisher's
exact test. The analyses were performed using Statview
4.02 and Splus 3.2. Differences were considered
significant at P < 0.05, and no adjustment was made
for multiple outcome testing.
RESULTS
Eighty patients, 77 females and three men, aged
33.2 ± 12 yr (mean ± S.D.), fulfilling the classification
criteria of SLE [10] were studied. Fifty-three were
Caucasians, 15 Afro-Caribbeans, nine Asians and three
were of mixed ethnic origin. Damage could be scored
at 1 yr after diagnosis in all 80 patients and at 5 yr in
76 patients; three had died and one had moved away.
At 10 yr, the DS could be determined in 68 patients—
six had died and six had moved away. Thus, by the end
of the study, lOyr after establishing the diagnosis of
TABLE u
SLE patients who died
Patient
9, Afro-Caribbean
9, Afro-Caribbean
9, Afro-Caribbean
9, Afro-Caribbean
9, Caucasian
9, Caucasian
9, Caucasian
9, Caucasian
9, Caucasian
9, Caucasian
Age (yr) at
diagnosis
31.6
15.1
14.8
35.2
48.8
24.3
31.4
52.4
27.5
21.6
Pulmonary
DS at 1 yr*
0
0
0
It
0
0
0
0
0
It
Cause of death
(important comorbidity)
Myocardial infarction (ESRF)
Myocarditis
Peritoneal sepsii (ESRF)
Thrombotic thrombopenic purpura
Hepatic failure
Thrombotic thrombopenic purpura
Myocardial infarction
Sepsis (Hodgkin's lymphoma)
Massive pulmonary embolism
Cardiac arrest
Years from
diagnosis to death
4
1.2
8.8
0.8
9.7
5
8.1
3.4
7
0.6
'Pulmonary damage score 1 yr after diagnosis, or in case of a lethal outcome earlier than 1.5 yr after diagnosis 6 months before death,
respectively.
jPulmonary fibrosis.
{Pulmonary hypertension.
TABLE m
Progression of damage scores and cumulative prevalence of damage* over time (* - percentage of patients with a DS > 0)
DS: mean (range); cumulative DS: mean (range); cumulative DS: mean (range); cumulative
Time after diagnosis prevalence of damage at 1 VT prevalence of damage at 5 yr prevalence of damage at 10 yr
Total damage score (unweighted)
Weighted damagr. score (total)
Ocular damage score
Neuropsychiatric damage score
Renal Hamagu score
Pulmonary damage score
Cardiovascular damage score
Peripheral vascular damage score
Gastrointestinal damage score
Musculoskeletal damage score
Skin damage score
Gonadal damage score
Endocrine, malignanry Harnagr
score
0.40 (0-3); 32.5%
1.19 (0-8); 32.5%
0.00 (0); 0%
0.08 (0-1); 7.5%
0.05 (0-1); 5%
0.05 (0-1); 5%
0.03 (0-1); 2.5%
0.03 (0-1); 2.5%
0.03 (0-1); 15%
0.11 (0-1); 11.3%
0.04 (0-1); 3.8%
0.00 (0); 0%
0.00 (0); 0%
0.75 (0-4); 51.3%
132 (0-13); 51.3%
0.00 (0); 0V.
0.13 (0-1); 13.2%
0.24(0-3); 17.1%
0.04 (0-1); 3.9%
0.04 (0-1); 3.9%
0.08 (0-1); 6.6%
0.04 (0-1); 3.9%
0.15 (0-2); 13.2%
0.07 (0-1); 6.6%
0.01 (0-1); 1.3%
0.00 (0); 0%
1.50 (0-5); 67.6%
4.81 (0-15); 67.6%
0.04 (0-1); 3.8%
0.24 (0-2); 22.1%
0.53 (0-3); 32.4%
0.09 (0-2); 7.4%
0.09 (0-1); 8.8%
0.12 (0-2); 10.3%
0.03 (0-1); 2.9%
0.31 (0-2); 22.1%
0.06 (0-1); 5.9%
0.03 (0-1); 2.9%
0.00 (0); 0%
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TABLE IV
Damage scores [only DS of organ (systems) with statistically significant differences shown] in different outcome groups at 1, 5 and 10 yr after
diagnosis
Damage score at
Outcome
Survival, DS
Mean
Range
Death, DS
Mean
Range
No ESRF, DS
Mean
Range
ESRF, DS
Mean
Range
*P < 0.05; f
Total
0.37
0-3
0.60
0-1
0.39
0-3
0.50
0-1
<0.01;
1
Weighted
1.14
0-8
1.50
0 - 4
1.16
0-8
1.50
0 - 4
IP < 0.001.
y
Renal
0.04
0-1
0.10
0-1
0.03t
0-1
0.33t
0-1
Pulmonary
0.03J
0-1
0.20J
0-1
0.05
0-1
0.00
0
Total
0.70
0-3
1.29
0-4
0.69*
0-3
1.50*
0-4
5yr
Weighted
2.19
0-12
3.57
0-13
2.04t
0-12
5.5Ot
0-13
Renal
0.20
0-3
0.57
0-3
0.14}
0-2
1.33J
0-3
Pulmonary
0.03
0-1
0.14
0-1
0.04
0-1
0.00
0
Total
1.52
0-5
1.25
0-2
1.40*
0-5
2.80*
2-3
lOyr
Weighted
4.83
0-15
4.50
0-8
4.3Ot
0-15
• 11.20t
8-12
Renal
0.53
0-3
0.50
0-2
0.35t
0-2
2.8Of
2-3
Pulmonary
0.06*
0-1
0.50*
0-2
0.10
0-2
0.00
0
SLE, 10 patients had died, on average 4.9 ± 3.4 yr after
diagnosis, at a mean age of 35.1 yr (in those four
patients who died between 7 and 9.7 yr after diagnosis,
a MOyr DS' 6 months before death was determined).
By 10 yr, six patients had developed ESRF, on average
7.2 ± 3 yr after diagnosis, at a mean age of 36.9 yr.
Table II shows the data of the 10 patients who died.
DS progressed with disease duration (Table III).
A decrease of DS, such as in the pulmonary,
gastrointestinal or skin item of the SLICC/ACR
Damage Index, reflects the finding that some patients
with a higher DS had either died or moved away (Table
m).
Damage scores in different outcome groups
In 10 and six patients, a search was made for
predictors for two major outcomes within the first 10 yr
after diagnosis: death and ESRF (Table IV). The
mean pulmonary DS at 1 yr in surviving patients was
significantly lower compared to those who had died
(P = 0.0095). The mean renal DS at 1 yr of those
patients developing ESRF was significantly higher than
the corresponding mean in the patients with no ESRF
up to 10 yr after diagnosis (P = 0.008). The increased
renal DS at 1 yr in those patients developing ESRF was
due to proteinuria ^3.5g/day. In those two patients
with a renal DS of 0 at 5 yr, at the end of the second
year after diagnosis a proteinuria of 0.5 and 1.1 g/day,
respectively, as expression of lupus nephritis was
present, but proteinuria in this range does not score as
damage. The earliest ESRF was observed 2.96 yr after
diagnosis. Figures 1 and 2 depict all these findings as
Kaplan-Meier survival curves. Table IV also outlines
the significant differences in pulmonary, renal, total
and weighted DS at 5 and lOyr beween outcome
groups. The strong association of renal DS and ESRF
at 5 and at 10 yr was to be expected as ESRF is
identical with a renal DS of 3.
Damage scores and outcomes in different ethnic groups
In the comparison between ethnic groups, patients of
mixed origin were not included in the analysis because
of their small number (n = 3). Age at diagnosis did not
differ between Caucasians (n = 53; age at diagnosis
35 ± 12.7 yr), Afro-Caribbeans (n = 15; 30.9 ± 11.5 yr)
and Asians (n = 9; 28.7 ± 6.5 yr) (P = 0.27). No
0 2 4 6 8
years after diagnosis of SLE
Flo. 1.—Survival (Kaplan-Meier) depending on the pulmonary DS
at 1 yr (SP1).
0 2 4 6 8 10
years after diagnosis of SLE
Fio. 2.—Survival to endstage renal failure (Kaplan-Meier) depend-
ing on the renal DS at 1 yr (SRI).
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statistically significant differences could be observed
1 yr after diagnosis. However, the mean total and renal
DS at 5 yr in Afro-Caribbeans were significantly
higher than in Caucasians (P = 0.049 and P = 0.036,
respectively). The mean weighted and neuropsychiatric
DS at 5 yr in Asians were significantly higher than in
Caucasians (P = 0.034 and P = 0.027, respectively).
Thus, the development of significant differences
occurred between 1 and 5 yr after diagnosis. The
differences between ethnic groups at 10 yr resembled
those noticed after 5 yr: mean total, weighted and renal
DS in Afro-Caribbeans and Asians were significantly
higher than in Caucasians (see Table V). Moreover,
Caucasians developed ESRF less frequently than
patients of other ethnic origins (P = 0.006). This
correlates with the finding that at 10 yr renal damage
was significantly less common in Caucasians (20.8%)
than in Afro-Caribbeans (63.6%) and Asians (57.1%)
(P = 0.006).
Comparison of total and weighted damage score
Table IV demonstrates that there was slightly more
statistical power resulting from the comparison of
weighted DS than from the comparison of total DS:
P = 0.008 and P = 0.007 vs P = 0.034 and P = 0.034
(outcome ESRF, 5 and 10 yr after diagnosis). The sole
statistically significant difference between Caucasians
and Afro-Caribbeans at 5 yr was observed when total
DS were compared, whereas between Caucasians and
Asians at 5 yr only weighted DS differed significantly.
DISCUSSION
By definition, the SLICC/ACR Damage Index scores
cumulative damage since the onset of SLE and is
therefore likely to increase with disease progression [1].
The mean pulmonary DS 1 yr after diagnosis
significantly predicted death. The relevant items in
those who died were either pulmonary fibrosis or
pulmonary hypertension (Table II). This was
predictable, as interstitial lung disease [11] and pul-
monary hypertension in SLE [12] are known to increase
mortality. The mean renal DS at 1 yr significantly
correlated with the development of ESRF. This
corresponds with the known prognostic value of
reduced glomerular filtration rate or proteinuria for
poor renal outcome [3,4]. Moreover, significantly
higher renal DS after 5 and 10 yr in patients with ESRF
appear to corroborate these findings. It is noteworthy
that the significant differences in mean total and
weighted DS at 5 and lOyr seem to reflect to a great
extent the differences in renal DS. These two
findings, being in accordance with the literature
[3,4,11,12], demonstrate prognostic validity for the
pulmonary and renal item of the SLICC/ACR Damage
Index.
Other organ DS, e.g. the neuropsychiatric or the
cardiovascular, or the total DS did not show
prognostic value in the present study.
Our report is the first to describe ethnic differences
by means of the SLICC/ACR Damage Index
(Table V). Significant differences in renal, neuro-
psychiatric and total DS developed between 1 and 5 yr
after diagnosis, as have been described previously for
both renal [13] and neuropsychiatric involvement
[14,15] within 5yr of diagnosis. However, our data
suggest that disease progression within the first 10 yr in
Caucasians is slower than for Afro-Caribbeans or
Asians. Compared to Caucasians, significantly higher
mean renal DS at 5 and 10 yr in Afro-Caribbeans
[6, 16, 17], and at 10 yr in Asians [18,19], respectively,
generally correspond to the literature. The significantly
lower occurrence of ESRF in Caucasians, compared to
the other ethnic groups, confirms these results.
Moreover, a higher mean neuropsychiatric DS 5 yr
after diagnosis in Asians than in Caucasians was found.
This difference, which is no longer significant at 10 yr,
may have occurred by chance. These data demonstrate
the discriminatory validity of the renal item of the
SLICC/ACR Damage Index, as most significant
differences between ethnic groups are corroborated by
being present on at least two assessments (Tables IV
and V) and above all are in accordance with reports
from other groups [13-19].
Statistical power was slightly increased when using
the weighted instead of the total DS in terms of
comparing different outcomes overall, though not for
comparison of ethnic groups (Tables IV and V).
Therefore, the weighted DS offers little advantage
compared to the total DS.
We noted a rather low prevalence of different organ
involvement, e.g. 13% neuropsychiatric disease at 5 yr
and 24% at 10 yr after diagnosis compared to figures
of CNS involvement of 12-59% reported by other
groups [20]. However, the SLICC/ACR Damage Index
scores only those items likely to be relevant to outcome.
Migraine, a frequent neuropsychiatric finding in SLE
patients, will not score as damage. Moreover, a
symptom/finding has to be present continuously for at
least 6 months to score. Finally, assessment by the
SLICC/ACR Damage Index is designed to be feasible
for all physicians to complete, being based on clinical
examination and simple investigations (urinalysis,
creatinine, X-ray of the chest). Subtle changes such as
cognitive impairment will only be scored when they are
clinically overt. However, such impairment demon-
strable with detailed neuropsychiatric testing or MRI
will not be counted as damage in a patient who seems
clinically unaffected.
In conclusion, in this study a severe outcome in
patients with SLE correlates significantly with a higher
mean renal or pulmonary DS at 1 yr. Renal (and
total) DS at 5 and 10 yr after diagnosis were
significantly higher in Asians and Afro-Caribbeans
than in Caucasians. Moreover, as our results are in
accordance with the literature prior to the use of the
SLICC/ACR Damage Index, they confirm the validity
of the SLICC/ACR Damage Index, especially of its
renal and pulmonary items. However, because of the
size of the studied retrospective cohort, these findings
warrant further evaluation in prospective studies with
greater numbers of patients.
TABLE V
Total, weighted, renal neuropsychiatrk («=• neurop.) and pulmonary ( = pulm.) damage in different ethnic groups at 1, 5 and 10 yr [only DS of organ (systems) with statistically significant
differences and pulmonary DS shown]
Ethnic group
Caucasians, DS
Mean
Range
Afro-Caribbeanj, DS
Mean
Range
Asians, DS
Mean
Range
Mixed,§ DS
Mean
Range
Total
0.32
0-2
0.67
0-3
0.56
0-2
0
0
Weighted
1.02
0-8
1.73
0-7
1.67
0-5
0
0
lyr
Renal
0.04
0-1
0.07
0-1
0.11
0-1
0
0
Neurop.
0.06
0-1
0.13
0-1
0.11
0-1
0
0
Pulm.
0.04
0-1
0.07
0-1
0.11
0-1
0
0
Total
0.56*
0-2
1.42*
0-4
1.11
0-3
0.33
0-1
Damage score
Weighted
1.69*
0-8
4.58
0-13
3.56*
0-8
0.33
0-1
5yr
Renal
0.12*
0-1
0.75*
0-3
0.22
0-1
0.33
0-1
at
Neurop.
0.08*
0-1
0.17
0-1
0.33*
0-1
0.33
0-1
Pulm.
0.04
0-1
0
0
0.11
0-1
0
0
Total
1.15Jf
0-5
2.55 t
2-3
2.57f
1-4
0.50
0-1
Weighted
3.60tt
0-15
8.73 t
5-12
8.14t
2-12
0.50
0-1
10 yr
Renal
0.27f*
0-2
1.36f
0-3
1.00*
0-3
0.50
0-1
Neurop.
0.17
0-1
0.36
0-1
0.43
0-2
0.50
0-1
Pulm.
0.1
0-2
0
0
0.14
0-1
0
0
*P <0.05; f^ <0.01; %P < 0.001.
{Because of the small number (n — 3), not included in statistical analysis.
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